Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression

Min-Soo Lee, R. H. Kang, H. S. Chang, M. L. Wong, M. J. Choi, Ji-Young Park, H. Y. Lee, I. K. Jung, S. H. Joe, Leen Kim, Seung Hyun Kim, Yong Ku Kim, Changsu Han, Byung-Joo Ham, Heon-Jeong Lee, Young-Hoon Ko, Moon-Soo Lee

Research output: Contribution to journalArticle

34 Citations (Scopus)

Abstract

Brain-derived neurotrophic factor (BDNF) is a candidate molecule for influencing the clinical response to antidepressant treatment. The aims of this study were to determine the relationship between the Val66Met polymorphism in the BDNF gene and the response to mirtazapine in 243 Korean subjects with major depressive disorder (MDD). The reduction in the Hamilton Depression score over the 8-week treatment period was not influenced by BDNF V66M genotypes. A marginal effect of genotype on somatic anxiety score was observed at baseline (P = 0.047 in the dominant model). However, genotype-time interaction had no effect on somatic anxiety score after the 8-week a treatment period. Plasma BDNF levels tended to increase during mirtazapine treatment, although without statistical significance (P = 0.055). After 8 weeks of mirtazapine treatment, plasma BDNF levels were higher in Met allele homozygotes (1499.7 ± 370.6 ng/mL) than in Val allele carriers (649.7 ± 158.5 ng/mL, P = 0.049). Our results do not support the hypothesis that the Val66Met promoter polymorphism in the BDNF gene influences the therapeutic response to mirtazapine in Korean MDD patients. However, our data indicate that this polymorphism results in increased plasma BDNF after mirtazapine treatment.

Original languageEnglish
Pages (from-to)1755-1763
Number of pages9
JournalJournal of Psychopharmacology
Volume24
Issue number12
DOIs
Publication statusPublished - 2010 Dec 1

Fingerprint

Brain-Derived Neurotrophic Factor
Depression
Genes
Genotype
Major Depressive Disorder
Therapeutics
Anxiety
Alleles
Homozygote
mirtazapine
Antidepressive Agents

Keywords

  • brain-derived neurotrophic factor
  • gene polymorphisms
  • major depression
  • mirtazapine
  • treatment response

ASJC Scopus subject areas

  • Pharmacology
  • Pharmacology (medical)
  • Psychiatry and Mental health

Cite this

Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression. / Lee, Min-Soo; Kang, R. H.; Chang, H. S.; Wong, M. L.; Choi, M. J.; Park, Ji-Young; Lee, H. Y.; Jung, I. K.; Joe, S. H.; Kim, Leen; Kim, Seung Hyun; Kim, Yong Ku; Han, Changsu; Ham, Byung-Joo; Lee, Heon-Jeong; Ko, Young-Hoon; Lee, Moon-Soo.

In: Journal of Psychopharmacology, Vol. 24, No. 12, 01.12.2010, p. 1755-1763.

Research output: Contribution to journalArticle

@article{21517a3e42d7469f9ef0a29dc23d363f,
title = "Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression",
abstract = "Brain-derived neurotrophic factor (BDNF) is a candidate molecule for influencing the clinical response to antidepressant treatment. The aims of this study were to determine the relationship between the Val66Met polymorphism in the BDNF gene and the response to mirtazapine in 243 Korean subjects with major depressive disorder (MDD). The reduction in the Hamilton Depression score over the 8-week treatment period was not influenced by BDNF V66M genotypes. A marginal effect of genotype on somatic anxiety score was observed at baseline (P = 0.047 in the dominant model). However, genotype-time interaction had no effect on somatic anxiety score after the 8-week a treatment period. Plasma BDNF levels tended to increase during mirtazapine treatment, although without statistical significance (P = 0.055). After 8 weeks of mirtazapine treatment, plasma BDNF levels were higher in Met allele homozygotes (1499.7 ± 370.6 ng/mL) than in Val allele carriers (649.7 ± 158.5 ng/mL, P = 0.049). Our results do not support the hypothesis that the Val66Met promoter polymorphism in the BDNF gene influences the therapeutic response to mirtazapine in Korean MDD patients. However, our data indicate that this polymorphism results in increased plasma BDNF after mirtazapine treatment.",
keywords = "brain-derived neurotrophic factor, gene polymorphisms, major depression, mirtazapine, treatment response",
author = "Min-Soo Lee and Kang, {R. H.} and Chang, {H. S.} and Wong, {M. L.} and Choi, {M. J.} and Ji-Young Park and Lee, {H. Y.} and Jung, {I. K.} and Joe, {S. H.} and Leen Kim and Kim, {Seung Hyun} and Kim, {Yong Ku} and Changsu Han and Byung-Joo Ham and Heon-Jeong Lee and Young-Hoon Ko and Moon-Soo Lee",
year = "2010",
month = "12",
day = "1",
doi = "10.1177/0269881109105457",
language = "English",
volume = "24",
pages = "1755--1763",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "12",

}

TY - JOUR

T1 - Brain-derived neurotrophic factor gene polymorphisms and mirtazapine responses in Koreans with major depression

AU - Lee, Min-Soo

AU - Kang, R. H.

AU - Chang, H. S.

AU - Wong, M. L.

AU - Choi, M. J.

AU - Park, Ji-Young

AU - Lee, H. Y.

AU - Jung, I. K.

AU - Joe, S. H.

AU - Kim, Leen

AU - Kim, Seung Hyun

AU - Kim, Yong Ku

AU - Han, Changsu

AU - Ham, Byung-Joo

AU - Lee, Heon-Jeong

AU - Ko, Young-Hoon

AU - Lee, Moon-Soo

PY - 2010/12/1

Y1 - 2010/12/1

N2 - Brain-derived neurotrophic factor (BDNF) is a candidate molecule for influencing the clinical response to antidepressant treatment. The aims of this study were to determine the relationship between the Val66Met polymorphism in the BDNF gene and the response to mirtazapine in 243 Korean subjects with major depressive disorder (MDD). The reduction in the Hamilton Depression score over the 8-week treatment period was not influenced by BDNF V66M genotypes. A marginal effect of genotype on somatic anxiety score was observed at baseline (P = 0.047 in the dominant model). However, genotype-time interaction had no effect on somatic anxiety score after the 8-week a treatment period. Plasma BDNF levels tended to increase during mirtazapine treatment, although without statistical significance (P = 0.055). After 8 weeks of mirtazapine treatment, plasma BDNF levels were higher in Met allele homozygotes (1499.7 ± 370.6 ng/mL) than in Val allele carriers (649.7 ± 158.5 ng/mL, P = 0.049). Our results do not support the hypothesis that the Val66Met promoter polymorphism in the BDNF gene influences the therapeutic response to mirtazapine in Korean MDD patients. However, our data indicate that this polymorphism results in increased plasma BDNF after mirtazapine treatment.

AB - Brain-derived neurotrophic factor (BDNF) is a candidate molecule for influencing the clinical response to antidepressant treatment. The aims of this study were to determine the relationship between the Val66Met polymorphism in the BDNF gene and the response to mirtazapine in 243 Korean subjects with major depressive disorder (MDD). The reduction in the Hamilton Depression score over the 8-week treatment period was not influenced by BDNF V66M genotypes. A marginal effect of genotype on somatic anxiety score was observed at baseline (P = 0.047 in the dominant model). However, genotype-time interaction had no effect on somatic anxiety score after the 8-week a treatment period. Plasma BDNF levels tended to increase during mirtazapine treatment, although without statistical significance (P = 0.055). After 8 weeks of mirtazapine treatment, plasma BDNF levels were higher in Met allele homozygotes (1499.7 ± 370.6 ng/mL) than in Val allele carriers (649.7 ± 158.5 ng/mL, P = 0.049). Our results do not support the hypothesis that the Val66Met promoter polymorphism in the BDNF gene influences the therapeutic response to mirtazapine in Korean MDD patients. However, our data indicate that this polymorphism results in increased plasma BDNF after mirtazapine treatment.

KW - brain-derived neurotrophic factor

KW - gene polymorphisms

KW - major depression

KW - mirtazapine

KW - treatment response

UR - http://www.scopus.com/inward/record.url?scp=78650079772&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=78650079772&partnerID=8YFLogxK

U2 - 10.1177/0269881109105457

DO - 10.1177/0269881109105457

M3 - Article

VL - 24

SP - 1755

EP - 1763

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 12

ER -